Daraxonrasib trial data
Daraxonrasib, a KRAS inhibitor, stopped tumour growth in 90% of the 61 participants with advanced pancreatic cancer. More than 60% saw tumours shrink or disappear. One in 12 patients saw cancer become undetectable on CT scans after receiving the pill and chemotherapy. Dr. Wungki Park from Memorial Sloan Kettering Cancer Centre reported that the trial shows higher percentage tumour response rates and deeper responses, which may eventually translate into longer survival because of a near doubling in the duration of disease control. This progress matters to the 11,500 people diagnosed with the disease in Britain every year.
I find the ability to target RAS mutations impressive, as the drug binds to and shuts off mutations that drive tumour growth in most pancreatic cancers. Dr. Sam Godfrey from Cancer Research UK said, "What this new drug has done is it’s found a way of drugging the undruggable." He added, "We are finally seeing progress in pancreatic cancer, which is so long overdue." Although results are exciting, doctors stress this is not a cure. Most patients with advanced disease survive months, not years, and longer studies are required to see if remission is possible.
| Category | Data |
|---|---|
| Annual UK diagnoses | 11,500 |
| Annual UK deaths | 10,200 |
| Trial participants | 61 |
| Tumour growth inhibition | 90% |
| Shrinkage or disappearance | >60% |
| Undetectable on CT scans | ~8% |
Patient statistics and symptoms
The drug might also help patients with lung and ovarian cancers because those diseases can have similar mutations. Prof Elena Garralda, chair of the European cancer conference EORTC, said the combined treatment could potentially improve patients’ overall survival and the time before tumours grow again. I find the potential for such a wide application promising, though the clinical reality is that cancer often returns. Even when scans show no sign of disease, you do not know if a patient is cancer-free until more time passes. This remains true for the thousands of patients facing the disease every year. The harshness is evident in cases like actor Alan Rickman, who died in 2016 only five months after his diagnosis.
In Britain, 11,500 people receive a diagnosis each year, and around 10,200 die from the disease. Pancreatic cancer has the lowest survival rate of all common cancers in the UK. While chemotherapy can shrink tumours slightly, the cancer often grows again. Symptoms that people should monitor include jaundice, itchy skin, darker urine, paler stools, unexplained weight loss, tiredness, and high temperature.


